Joan C. Edwards School of Medicine, Marshall University, Huntington, WV 25701, USA.
J Oncol. 2011;2011:941876. doi: 10.1155/2011/941876. Epub 2010 Oct 12.
Despite advances in treatment, cancer remains the 2nd most common cause of death in the United States. Poor cure rates may result from the ability of cancer to recur and spread after initial therapies have seemingly eliminated detectable signs of disease. A growing body of evidence supports a role for cancer stem cells (CSCs) in tumor regrowth and spread after initial treatment. Thus, targeting CSCs in combination with traditional induction therapies may improve treatment outcomes and survival rates. Unfortunately, CSCs tend to be resistant to chemo- and radiation therapy, and a better understanding of the mechanisms underlying CSC resistance to treatment is necessary. This paper provides an update on evidence that supports a fundamental role for CSCs in cancer progression, summarizes potential mechanisms of CSC resistance to treatment, and discusses classes of drugs currently in preclinical or clinical testing that show promise at targeting CSCs.
尽管治疗方法有所进步,但癌症仍然是美国第二大常见死因。治疗效果不佳可能是由于癌症在初始治疗似乎消除了可检测到的疾病迹象后,仍有能力复发和扩散。越来越多的证据表明,癌症干细胞(CSC)在初始治疗后肿瘤的再生长和扩散中起作用。因此,将 CSC 作为靶点与传统诱导疗法联合使用可能会改善治疗效果和生存率。不幸的是,CSC 往往对化疗和放疗有抵抗力,因此需要更好地了解 CSC 抵抗治疗的机制。本文提供了支持 CSC 在癌症进展中起根本作用的证据更新,总结了 CSC 抵抗治疗的潜在机制,并讨论了目前处于临床前或临床测试阶段的、有望靶向 CSC 的药物类别。